Skip to content
  • Science
  • Sepranolone
  • Menstrual Migraine
  • Tourette Syndrome
  • PMDD
  • Investors
    • The Share
      • Shareholders
      • Analyst Coverage
      • IPO 2018
    • Calendar
    • Corporate Governance
      • EGM januari-20
      • Investor Relations
      • Articles of Association
      • Annual Meeting
    • Financial Reports
    • Subscribe
  • Press Releases
    • News
    • Media
    • Presentations
  • About Us
  • Contact
  • Investors
    • The Share
      • Shareholders
      • Analyst Coverage
      • IPO 2018
    • Calendar
    • Corporate Governance
      • EGM januari-20
      • Investor Relations
      • Articles of Association
      • Annual Meeting
    • Financial Reports
    • Subscribe
  • Press Releases
    • News
    • Media
    • Presentations
  • About Us
  • Contact
  • Science
  • Sepranolone
  • Menstrual Migraine
  • Tourette Syndrome
  • PMDD

EGM januari-20

Asarina Pharma – Bilaga 1A (fullständiga villkor för teckningsoptioner) (PDF)

Asarina Pharma – Fullmaktsformulär (PDF)

Asarina Pharma – Proxy Form (PDF)

Asarina Pharma – Styrelsens fullständiga förslag (PDF)

Asarina Pharma – Styrelsens redogörelse (PDF)

Asarina Pharma – Östersjöstiftelsens fullständiga förslag (PDF)

Asarina Pharma – Revisorns yttrande (PDF)

Asarina Pharma AB
Registered office in Solna, Sweden
Reg no 556698-0750
© All rights reserved

Navigation

  • Home
  • Science
  • Sepranolone
  • Menstrual Migraine
  • Tourette Syndrome
  • PMDD
  • Investors
  • Press Releases
  • About Us
  • Contact

Contact

Asarina Pharma AB
Karolinska Institutet Science Park
Fogdevreten 2
SE – 171 65 Solna, Sweden

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

This site uses cookies. By continuing to use this website you agree to our use of cookies. Accept
Read more about how we use cookies here. Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
SAVE & ACCEPT